<?xml version="1.0" encoding="UTF-8"?>
<p id="p0175">Several animal studies demonstrated that nAb, induced by vaccination or passively transferred in serum, is a correlate of protection against flavivirus challenge (
 <xref rid="bb0035" ref-type="bibr">Ben-Nathan et al., 2003</xref>, 
 <xref rid="bb0080" ref-type="bibr">Diamond et al., 2003</xref>, 
 <xref rid="bb0105" ref-type="bibr">Engle and Diamond, 2003</xref>, 
 <xref rid="bb0130" ref-type="bibr">Hammon and Sather, 1973</xref>, 
 <xref rid="bb0170" ref-type="bibr">Julander et al., 2011</xref>, 
 <xref rid="bb0180" ref-type="bibr">Kreil et al., 1997</xref>, 
 <xref rid="bb0185" ref-type="bibr">Kreil et al., 1998</xref>, 
 <xref rid="bb0205" ref-type="bibr">Lubiniecki et al., 1973</xref>, 
 <xref rid="bb0310" ref-type="bibr">Swanstrom et al., 2016</xref>, 
 <xref rid="bb0325" ref-type="bibr">Tesh et al., 2002</xref>). Specifically, in the case of ZIKV infection, recent studies evaluating multiple vaccine delivery formats have also provided compelling evidence that nAb is a likely CoP (
 <xref rid="bb0005" ref-type="bibr">Abbink et al., 2016</xref>, 
 <xref rid="bb0090" ref-type="bibr">Dowd et al., 2016</xref>, 
 <xref rid="bb0195" ref-type="bibr">Larocca et al., 2016</xref>, 
 <xref rid="bb0275" ref-type="bibr">Richner et al., 2017</xref>, 
 <xref rid="bb0280" ref-type="bibr">Sapparapu et al., 2016</xref>, 
 <xref rid="bb0360" ref-type="bibr">Zhao et al., 2016</xref>).
</p>
